Dicerna Posts Updated Data From Belcesiran Early-Stage Study For Genetic Liver Disease
Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) has announced interim results from the four completed active-treatment dose cohorts (0.1, 1.0, 3.0, and 6.0 mg/kg) of its Phase 1 trial of belcesiran.
- The GalXC RNAi therapeutic is in development for alpha-1 antitrypsin deficiency-associated liver disease (AATLD), a rare genetic condition that can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma.
- The primary treatment evaluation period for the final dose cohort (12.0 mg/kg) is ongoing.
- Mean maximum serum AAT reductions from baseline achieved for doses greater than 0.1 mg/kg were: 50% (1.0 mg/kg), 69% (3.0 mg/kg) and 80% (6.0 mg/kg).
- In the four subjects receiving 6.0 mg/kg, maximum AAT reductions of 91%, 87%, 79%, and 62% were observed. The latter participant experienced a concomitant skin infection (unrelated to belcesiran) and markedly elevated C-reactive protein levels (a measure of inflammation).
- There were no serious adverse events reported.
- Three moderate treatment-emergent adverse events were reported, though unrelated to belcesiran, the Company said.
- No clinically significant changes in lung function or laboratory tests were reported.
- Price Action: DRNA shares are down 5.51% at $37.78 during the premarket session on the last check Wednesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs Liver Disease Phase 1 TrialBiotech News Health Care General